![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 39, 36697-36705, September 27, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
andFrom the Department of Biochemistry, Duke University Medical Center, Durham, North Carolina 27710
Received for publication, June 12, 2002, and in revised form, July 10, 2002
| |
ABSTRACT |
|---|
|
|
|---|
Escherichia coli MsbA, the
proposed inner membrane lipid flippase, is an essential ATP-binding
cassette transporter protein with homology to mammalian multidrug
resistance proteins. Depletion or loss of function of MsbA results in
the accumulation of lipopolysaccharide and phospholipids in the inner
membrane of E. coli. MsbA modified with an N-terminal
hexahistidine tag was overexpressed, solubilized with a nonionic
detergent, and purified by nickel affinity chromatography to ~95%
purity. The ATPase activity of the purified protein was stimulated by
phospholipids. When reconstituted into liposomes prepared from E. coli phospholipids, MsbA displayed an apparent Km of 878 µM and a
Vmax of 37 nmol/min/mg for ATP hydrolysis in the presence of 10 mM Mg2+. Preincubation of
MsbA-containing liposomes with 3-deoxy-D-mannooctulosonic acid (Kdo)2-lipid A increased the ATPase activity
4-5-fold, with half-maximal stimulation seen at 21 µM
Kdo2-lipid A. Addition of Kdo2-lipid A
increased the Vmax to 154 nmol/min/mg and
decreased the Km to 379 µM.
Stimulation was only seen with hexaacylated lipid A species and not
with precursors, such as diacylated lipid X or tetraacylated lipid
IVA. MsbA containing the A270T substitution, which renders
cells temperature-sensitive for growth and lipid export, displayed
ATPase activity similar to that of the wild type protein at 30 °C
but was significantly reduced at 42 °C. These results provide the
first in vitro evidence that MsbA is a lipid-activated
ATPase and that hexaacylated lipid A is an especially potent activator.
The envelope of Escherichia coli and other
Gram-negative bacteria consists of an inner membrane, a periplasmic
space, and an outer membrane (1). The outer leaflet of the outer
membrane is composed of lipopolysaccharide
(LPS),1 a complex glycolipid
that is essential for an effective permeability barrier and is a potent
stimulator of the innate immune system in mammals (2-5). Lipid A is
the hydrophobic anchor of LPS (2-5). Lipid A biosynthesis is essential
for survival of most Gram-negative bacteria and is a target for the
design of new antibiotics (5-9).
The enzymes that catalyze the synthesis of Kdo2-lipid A,
the minimal lipid A required for survival in laboratory strains of E. coli, are cytoplasmic or associated with the
inner membrane (2, 3, 5). The mechanism by which E. coli
transports newly synthesized lipid A from its site of biosynthesis at
the inner face of the inner membrane to the outer membrane is not fully
understood. Recent studies from our laboratory have demonstrated that
export of both lipid A and glycerophospholipids requires the inner
membrane protein MsbA (10, 11), originally identified as a multicopy
suppressor of the temperature-sensitive growth phenotype of
lpxL(htrB) knockouts (12), a gene encoding a key late acyltransferase in the lipid A biosynthetic pathway (13, 14) (Fig.
1A). MsbA is a member of the
ATP-binding cassette (ABC) superfamily, is closely related to mammalian
multidrug-resistance (MDR) proteins, and is required for growth of
E. coli (12, 15). Zhou et al. (10) demonstrated
that depletion of cellular MsbA resulted in the gradual accumulation of
lipid A and glycerophospholipids in the inner membrane. More recently,
we have isolated a novel, temperature-sensitive E. coli
point mutant of MsbA (designated WD2) and have shown that loss of MsbA
function results in rapid cessation of cell growth, accompanied by
accumulation of lipid A and phospholipids in the inner membrane and
formation of inner membrane invaginations visible by electron
microscopy (11). MsbA in WD2 contains a single amino acid substitution
(A270T) located in its fifth transmembrane span (Fig. 1B).
Our genetic evidence strongly suggests that MsbA functions as a general
lipid transporter, or flippase, playing a key role in the movement of lipids from the inner membrane to the outer membrane of E. coli (11). Although there is no evidence that MsbA confers
multidrug resistance in E. coli, the related LmrA protein of
Lactococcus lactis does in fact confer resistance to many of
the same amphiphilic compounds that are transported by MDR1 (16,
17).
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (32K):
[in a new window]
Fig. 1.
Proposed role of E. coli
MsbA in phospholipid export and structure of the E. coli MsbA dimer at 4.5 Å resolution. A, after
the MsbA mediated flip-flop/transport of newly made hexaacylated lipid
A and phospholipids at the inner membrane (11), additional proteins are
likely to be involved in steps 2 and 3, but these have not yet been
identified. B, this backbone tracing of MsbA was made from
Protein Data Bank file 1JSQ (18). Transmembrane helices 1-6 are
colored purple, blue, yellow,
green, red, and orange, respectively.
The intracellular domain (ICD) is brown, and the
nucleotide binding domain (NBD) is cyan (18). A
schematic model of lipid A is shown for size comparison. The location
of the Ala-270 residue, which is changed to threonine in the
temperature-sensitive lipid transport mutant WD2 (11), is shown as a
red sphere. The putative chamber for the binding
of lipids on the inner surface of the inner membrane (18) is lined with
basic residues (not shown).
E. coli msbA encodes a 584-amino acid residue inner membrane protein (11, 12). It was predicted to contain a classical ABC domain at its C terminus and a hydrophobic region at its N terminus, consisting of six transmembrane spans (11, 12). The proposed topology and dimeric structure of MsbA were validated recently by the crystal structure (18) at 4.5 Å resolution (Fig. 1B). MsbA contains an intriguing cleft, oriented toward the cytoplasm, between its two subunits (Fig. 1B) (18). The cleft is lined with basic amino acids, and it is sufficient in size to accommodate lipid A or several glycerophospholipid molecules (18). ATP binding and hydrolysis presumably drive a conformational change that results in lipid extrusion to the periplasmic surface of the inner membrane (Fig. 1) (18). The A270T substitution is situated at a critical site near the periplasmic surface in the MsbA molecule (Fig. 1B), consistent with the lipid transport defect seen in WD2 at 42 °C.
Previous studies have shown that the intrinsic ATPase activity of MDR
proteins and other ABC transporters, when purified and reconstituted
into liposomes, can be stimulated by physiologic concentrations of
transported substrates (19-23). To develop functional assays for MsbA
and to elucidate its role in lipid export, we have expressed the
protein as an N-terminal hexahistidine fusion, purified it to near
homogeneity, and reconstituted it into liposomes. The ATPase activity
of purified MsbA is dependent upon the presence of phospholipids and is
stimulated further by Kdo2-lipid A.
| |
EXPERIMENTAL PROCEDURES |
|---|
|
|
|---|
Materials-- LDAO was purchased from Fluka Biochemika. DDM was purchased from Sigma. E. coli phospholipids were purchased from Avanti Polar Lipids, Inc. Bio-Beads were from Bio-Rad, and nickel-nitrilotriacetic acid-agarose resin was from Qiagen. Tryptone and yeast extract were from Difco. All other chemicals were reagent grade and purchased from either Sigma or Mallinckrodt.
Plasmid Construction-- The E. coli msbA gene was amplified from W3110 genomic DNA by PCR with Pfu turbo (Stratagene) according to the manufacturer's instructions. The forward primer was 5'-ATG CTG GTT TTT CAT ATG CAT AAC GAC-3' (NdeI site underlined), and the reverse primer was 5'-CGG GAT CCT CGA GTC ATT GGC CAA ACT GCA TTT TG-3' (BamHI site underlined). The msbA initiation and termination codons in the primers are italicized. These primers were used at a final concentration of 2.5 ng/µl in a 100-µl PCR mixture containing 100 ng of genomic DNA and 5 units of Pfu polymerase. The reaction conditions were as follows: a 94 °C denaturation for 1 min followed by 25 cycles of 94 °C (denature) for 1 min, 55 °C (anneal) for 1 min, and 72 °C (extension) for 2 min. This was followed by a 10-min runoff at 72 °C. The gel-purified PCR product was digested with NdeI and BamHI (New England Biolabs) and ligated into an NdeI/BamHI-digested and shrimp alkaline phosphatase (Roche Molecular Biochemicals)-treated pET28b vector (Novagen) to give vector pWTD1. Vector pWTD7, containing the temperature-sensitive MsbA allele (A270T), was constructed in an identical manner starting from genomic DNA from strain WD2 (11). Vector pWTD3 was constructed by cloning the XbaI/HindIII fragment of pWTD1 (containing the in-frame hexahistidine tag and ribosomal binding site) into an XbaI/HindIII and shrimp alkaline phosphatase-treated vector pACYC184 (New England Biolabs). All plasmids were sequenced at the Duke University sequencing facility and found to be free of errors. Genomic DNA was prepared using the Easy-DNA kit from Invitrogen.
Overexpression of N-His6-MsbA--
pWTD1 was
transformed into Novablue (DE3) cells (Novagen). A single
kanamycin-resistant colony was inoculated into 5 ml of LB broth (24)
(adjusted to pH 7.0 and containing 30 µg/ml kanamycin) and grown at
37 °C overnight. The overnight culture was diluted 100-fold into 500 ml of LB broth containing kanamycin, and the cells were grown at
37 °C until A600 reached 0.6. Isopropyl-1-thio-
-D-galactopyranoside was then added to
a final concentration of 1 mM. Growth was continued at
30 °C for 3 h, and cells were harvested by centrifugation at 6,000 × g for 15 min. All subsequent steps were
carried out at 0-4 °C. Cell pellets were resuspended in 50 ml of 50 mM HEPES buffer, pH 7.5, containing 5 mM
-mercaptoethanol and were broken by passage through a French
pressure cell at 18,000 p.s.i. The crude lysate was cleared by
centrifugation at 10,000 × g for 20 min. Membranes
were prepared by two sequential ultracentrifugation steps at
100,000 × g for 60 min with a wash of the first
membrane pellet in 10 ml of 50 mM HEPES buffer, pH 7.5, 500 mM NaCl, 5 mM MgCl2, 10% glycerol,
and 5 mM
-mercaptoethanol (buffer A). The final membrane
pellet was homogenized in buffer A at a protein concentration of ~5
mg/ml.
Solubilization and Purification of N-His6-MsbA-- LDAO was added to the washed membranes (5 mg/ml in buffer A) to a final concentration of 2% (w/v) and incubated with rotation for 1 h at 4 °C. Insoluble material was removed by ultracentrifugation at 125,000 × g for 1 h. The soluble fraction was adjusted to 10 mM imidazole and loaded onto a preequilibrated nickel-nitrilotriacetic acid-agarose column. After washes with 5 column volumes of 10 mM and then with 5 column volumes of 50 mM imidazole in buffer A containing 0.1% DDM, protein was eluted with 5 column volumes of 200 mM imidazole in buffer A containing 0.1% DDM.
Reconstitution of Purified N-His6-MsbA--
For
reconstitution of the purified protein, E. coli
phospholipids (polar lipid extract, Avanti) were dried under a stream of nitrogen and then subjected to sonic irradiation for 5 min in a bath
sonicator at a concentration of 25 mg/ml in 50 mM HEPES, pH
7.5, containing 50 mM NaCl, 5 mM
MgCl2, and 2 mM
-mercaptoethanol. The
liposomes were frozen on dry ice, thawed slowly at room temperature, and then homogenized by five passages through a 27-gauge needle. The
liposomes were diluted to a concentration of 4 mg/ml in the above
buffer, and DDM was added to solubilize the system to generate mixed
micelles (1 µmol of DDM/mg of lipid). Solubilization was followed
spectrophotometrically at 540 nm (25). Purified
N-His6-MsbA was added to the lipid/DDM mixed
micelles at a protein:lipid ratio of 1:100 (w/w). The mixture was
incubated with gentle agitation at room temperature for 30 min.
Bio-Beads (previously washed extensively with methanol and then water)
were added at 80 mg/ml. The system was incubated for 2 h at
4 °C and then for 2 h and for 16 h at 4 °C after the
addition of fresh Bio-Beads. The final proteoliposomes were isolated by
ultracentrifugation at 125,000 × g for 1 h at 4 °C. They were resuspended at 0.25 mg of protein/ml in buffer A
containing 1 mM dithiothreitol instead of
-mercaptoethanol and stored at
80 °C. All ATPase assays were
carried out using proteoliposomes that had undergone a freeze/thaw step
and had been passed through a 27-gauge needle several times.
ATPase Assay-- Purified MsbA protein in 0.1% DDM or reconstituted into vesicles was assayed for ATPase activity at a protein concentration of ~1-10 µg/ml in a 150-µl reaction mixture containing (final concentrations) 50 mM HEPES, adjusted to pH 7.5 with NaOH, 10 mM MgCl2, 1 mM dithiothreitol, and 2 mM ATP. In assays containing 0.1% DDM, 10% glycerol was also included. If exogenous lipids or inhibitors were included in the assay, a 15-min preincubation of all components on ice was included before the incubation at 37 °C. ATPase reactions were incubated for the indicated times at 37 °C and stopped by the addition of 150 µl of 12% SDS. The amounts of Pi released were determined by a colorimetric method, as described by Gonzalez-Romo et al. (26), using potassium phosphate as the standard. After the addition of SDS, 300 µl of a solution containing equal volumes of 12% ascorbic acid in 1 M HCl and 2% ammonium molybdate in 1 M HCl was added, and the samples were incubated at room temperature for 5 min. This was followed by the addition of 450 µl of an aqueous solution of 2% sodium citrate, 2% sodium metaarsenite, and 2% acetic acid. After a 20-min incubation at room temperature, absorbance was measured at 850 nm. The assay was linear in the range of 6-400 µM Pi.
Isolation of Kdo2-Lipid A--
WBB06 cells (27) were
grown overnight at 37 °C to A600 ~3.5 in 2 liters of LB broth adjusted to pH 7.0 and supplemented with 12 µg/ml
tetracycline. Cells were harvested by centrifugation at 6,000 × g for 10 min, washed with an equal volume of
phosphate-buffered saline (28), and resuspended in 160 ml of
phosphate-buffered saline. Chloroform and methanol were added to give a
single-phase Bligh-Dyer mixture consisting of
chloroform:methanol:phosphate-buffered saline (1:2:0.8, v/v) (29). The
cells were extracted for 1 h at room temperature with frequent
mixing. Insoluble material was removed by centrifugation at 3,000 × g for 10 min, and the supernatant, containing the
glycerophospholipids and Kdo2-lipid A, was removed. It was
converted to a two-phase Bligh-Dyer system by the addition of
chloroform and water to give the mixture chloroform:methanol:water (2:2:1.8, v/v) (29). After thorough mixing, the phases were separated
by centrifugation as described above, and the upper phase was washed
with a fresh, preequilibrated Bligh-Dyer lower phase. The lower phases
were pooled, washed once with a fresh, preequilibrated Bligh-Dyer upper
phase, and dried in a rotary evaporator. The dried lipids were
redissolved in 10 ml of chloroform:methanol:water (2:3:1, v/v) and
applied to a 2-ml DEAE-cellulose column (Whatman DE52), equilibrated as
the acetate form in the same solvent mixture (30, 31). The column was
washed with 2 column volumes of chloroform:methanol:water (2:3:1, v/v)
and eluted with 5 column volumes each of chloroform:methanol:aqueous ammonium acetate (at 60, 120, 240, 360, or 480 mM) (2:3:1,
v/v) (31) while collecting 2-ml fractions throughout the elution. Phosphatidylethanolamine was not bound to the column, whereas phosphatidylglycerol and other phospholipids eluted in the 60-120 mM fractions. The Kdo2-lipid A
1,4'-bis-phosphate species eluted in the 240 mM
fraction, but the Kdo2-lipid A 1-pyrophosphate variant (32,
33) eluted in the 360 mM fractions. The fractions
containing the purified Kdo2-lipid A
1,4'-bis-phosphate were pooled and converted to a neutral
two-phase Bligh-Dyer system by the addition of appropriate amounts of
chloroform and water. The lower phase was neutralized with a few drops
of pyridine and was dried under a stream of nitrogen. It was then
resuspended with sonic irradiation for 2 min in a bath apparatus in 20 mM HEPES, pH 7.5, and stored at
80 °C. The elution of
the various lipids from the DEAE column was monitored by spotting
~5-µl samples onto Silica Gel 60 TLC plates followed by development
in a solvent containing chloroform, pyridine, 88% formic acid, and
water (50:50:16:5, v/v), and visualization by sulfuric acid charring.
The amount of purified lipid was quantified by complete acid hydrolysis
in 50 µl of 5 M HCl at 100 °C for 16 h followed
by measurement of the released Pi, using the phosphate assay described above (26). Potassium phosphate samples were run in
parallel to generate a standard curve. The final yield of
Kdo2-lipid A 1,4'-bis-phosphate was ~5 mg from
2 liters of cells. The Kdo2-lipid A from strain WBB06 was
greater than 95% pure as judged by TLC analysis followed by sulfuric
acid charring, and by matrix-assisted laser desorption ionization
time-of-flight mass spectrometry (data not shown).
Lipid X was isolated from E. coli MN7 (34) as described by Radika and Raetz (35). Lipid IVA was prepared according to the procedure of Garrett et al. (36) and was a gift from Dr. Stephen Trent of this laboratory. RaLPS (3) was purchased from Sigma and suspended at a concentration of 1 mM (molecular weight ~4,000) in 20 mM HEPES, pH 7.5. Free hexaacylated lipid A was prepared by pH 4.5 hydrolysis at 100 °C from either RaLPS or Kdo2-lipid A (10), and quantified by phosphate assay as described above. All lipids suspended in aqueous buffers were dispersed before use by sonic irradiation for 1 min in a bath sonicator.
Analytical Methods--
Protein samples were denatured at
100 °C for 5 min and analyzed by 12% SDS-PAGE followed by Coomassie
staining. Prestained low range standards from Bio-Rad were used to
estimate protein molecular weights. Protein concentrations were
determined with the Coomassie Plus Protein Assay Reagent (Pierce) using
bovine serum albumin as the standard.
| |
RESULTS |
|---|
|
|
|---|
Overexpression and Purification of E. coli MsbA-- To facilitate purification, the E. coli msbA gene was cloned into pET28b behind the T7 promoter in-frame with an N-terminal His6 tag. This expression plasmid was designated pWTD1 (Table I). The His-tagged protein, when expressed on the low copy vector pWTD3 (a pACYC184 derivative), was functional as judged by its ability to complement the growth at 44 °C of the MsbA temperature-sensitive mutant WD2 (data not shown).
|
Membranes prepared from cells overexpressing msbA on pWTD1
contained large amounts of a protein migrating at a molecular
mass of ~65 kDa which was absent in cells harboring pET28b
(Fig. 2). The His-tagged MsbA fusion
protein was solubilized efficiently from membranes using 2% LDAO and
was purified by nickel affinity chromatography (Fig. 2). During
chromatography the detergent was changed to DDM. The protein was
greater than 95% pure as judged by SDS-PAGE and Coomassie Blue
staining (Fig. 2). A typical preparation yielded ~3 mg of purified
MsbA protein from 30 mg of washed membranes.
|
ATPase Activity of Detergent-solubilized, Purified MsbA in the
Presence or Absence of Added Lipids--
Using a colorimetric assay
for released Pi (26), we found that the ATPase specific
activity of the purified, detergent-solubilized MsbA was low, typically
in the range of 2-4 nmol/min/mg (Fig. 3,
top panel). The addition of E. coli
phospholipids to the assay system at concentrations above 2 mg/ml
greatly stimulated and stabilized the ATPase activity (Fig. 3,
middle panel). Phospholipids at 2 mg/ml or above would be
expected to form vesicles, even in the presence of 0.1% (1 mg/ml) DDM.
However, the addition of Kdo2-lipid A at low micromolar
concentrations also resulted in stimulation of ATPase activity (Fig. 3,
bottom panel). At this relatively low concentration the
lipid should form mixed micelles with the nonionic detergent (37).
|
ATPase Activity Associated with Purified, Liposome-reconstituted
MsbA--
In light of the results shown in Fig. 3, we routinely
reconstituted the solubilized MsbA protein into liposomes at a
protein:lipid ratio of 1:100 (w/w). Proteoliposomes were prepared from
E. coli phospholipids and purified MsbA, both solubilized
with DDM, followed by treatment with Bio-Beads to remove the detergent
as described under "Experimental Procedures." The MsbA-containing
proteoliposomes were found to have an intrinsic ATPase activity that
was nearly linear with time at 37 °C for 2 h, and with a
protein concentration up to at least 2 µg/150 µl of reaction
mixture (Fig. 4, A and B). Using 2 mM ATP, a magnesium ion
concentration of 10 mM (Fig. 4C) and pH values
ranging from 7 to 8.5 (data not shown) were optimal. The
Vmax of the reconstituted protein was 37 nmol/min/mg, and the apparent Km for ATP was 878 µM (Fig. 5). These
parameters are in the same range as reported for the ABC transporters
cystic fibrosis transmembrane conductance regulator (CFTR), multidrug resistance protein 1 (MRP1), and rod photoreceptor-specific ABC transporter (ABCR) (21, 22, 38, 39). Proteoliposomes prepared from mock-purified extracts of vector (pET28b)-containing control cells
were found to have a background activity that was indistinguishable from liposomes prepared in the absence of protein (data not shown). Therefore, in the experiments shown in Figs. 4 and 5, reaction mixtures
containing protein-free liposomes were run in parallel with the
MsbA-reconstituted liposomes and subtracted as nonenzymatic ATPase
blanks. In general these no-protein controls represented less than 10%
of the activity seen with reconstituted MsbA (data not shown).
|
|
Additional Stimulation of MsbA ATPase Activity by Hexaacylated
Lipid A--
In view of the genetic evidence that MsbA might function
both as a phospholipid and as a lipid A transporter (10, 11), we tested
the effect of hexaacylated Kdo2-lipid A on the ATPase activity of reconstituted MsbA in proteoliposomes.
Kdo2-lipid A isolated from a heptose-deficient mutant of
E. coli (27) was incubated at various concentrations either
with protein-free control liposomes or with MsbA-containing
proteoliposomes for 15 min at 0 °C immediately before the assay at
37 °C. The ATPase activity of MsbA increased as much as 5-fold over
the basal level seen in the absence of Kdo2-lipid A (Fig.
6A). Stimulation was
half-maximal at ~21 µM Kdo2-lipid A (Fig.
6A). The data suggest that MsbA may interact with
hexaacylated lipid A more strongly than with E. coli
glycerophospholipids, resulting in additional stimulation of ATPase
activity.
|
To investigate the structural specificity of the observed stimulation,
MsbA proteoliposomes were preincubated with other LPS preparations or
with lipid A precursors, each at ~100 µM, as well as
with phosphatidylcholine and cholesterol, which are not made by
E. coli. As illustrated in Fig. 6B, the
precursors lipid X and lipid IVA (Fig.
7) do not stimulate the ATPase activity
of MsbA above the levels achieved with glycerophospholipids alone. However, purified hexaacylated lipid A (lacking the Kdo region and
other core sugars), obtained by pH 4.5 sodium acetate hydrolysis of
LPS, also stimulates the ATPase activity of MsbA above the level seen
with reconstituted liposomes (Fig. 6B). Commercially available LPS from E. coli EH100 (which contains
hexaacylated lipid A and a complete core domain but lacks
O-antigen) likewise stimulates the ATPase activity of MsbA
(Fig. 6B) above the level seen with glycerophospholipids.
These observations are consistent with previous reports that lipid A
precursors are not transported to the outer membrane as rapidly as
hexaacylated lipid A is (40, 41).
|
The Vmax for ATP calculated in the presence of 50 µM Kdo2-lipid A increased from 37 to 154 nmol/min/mg, whereas the Km was decreased by more than half (Fig. 5). Effects of similar magnitude were reported for the Vmax and Km of reconstituted ABCR after preincubation with all-trans-retinal (21, 22). Taken together with previous genetic studies (10, 11), these results suggest that LPS species containing hexaacylated lipid A are recognized the most effectively by MsbA, although glycerophospholipids are stimulatory as well. The MsbA assays described in Figs. 3-7 should facilitate the search for specific small molecule inhibitors of MsbA, which might be useful as leads for novel antibiotics.
The eukaryotic lipids cholesterol and phosphatidylcholine have no effect in stimulating the MsbA ATPase above the liposome background (Fig. 6B). In some mammalian tissues, cholesterol efflux is mediated by the ABCA1 protein (42-44), an ABC transporter defective in Tangier disease (45-47).
Additional Characterization of the MsbA ATPase Activity--
The
effects on MsbA of known inhibitors or activators of previously
characterized ABC transporters were assessed. Sodium
ortho-vanadate (or one of its oligomeric forms present in
solution) is a potent inhibitor of the P-glycoprotein ATPase. Vanadate
is thought to block the catalytic cycle by forming a noncovalent
complex with MgADP at the ATPase site of the transporter (48, 49).
Vanadate inhibits the ATPase activity of reconstituted MsbA by about
70%, with half-maximal inhibition observed at ~35 µM
(Fig. 8). In contrast, sodium azide, an
inhibitor of SecA and F-type ATPases (50), had no effect on MsbA (data
not shown). Substrates of Mdr1, like verapamil, doxorubicin,
vinblastine, daunomycin, or colchicines (16, 51), likewise had no
effect on the ATPase activity of MsbA (data not shown).
|
Effect of the A270T Mutation on the ATPase Activity of MsbA-- The mutant WD2 contains a single amino acid substitution in MsbA (A270T) (Fig. 1B), which renders the cells temperature-sensitive for growth (11). WD2 cells stop dividing 1 h after a shift from the permissive temperature of 30 °C to 42 or 44 °C (11). Growth inhibition is accompanied by the accumulation of newly made lipid A and glycerophospholipids in the inner membrane (11). Concurrently, multiple inner membrane folds and invaginations become visible by electron microscopy (11).
MsbA (A270T) was amplified from WD2 genomic DNA, overexpressed,
purified, and reconstituted in the same manner as wild type MsbA. The
basal ATPase specific activities of both the wild type and mutant
proteins were measured at 30 and 42 °C. Interestingly, although both
proteins had similar ATPase activities at 30 °C, the mutant activity
was decreased significantly at 42 °C (Fig. 9). However, the -fold stimulation by
Kdo2-lipid A was similar for both proteins at both
temperatures (data not shown).
|
| |
DISCUSSION |
|---|
|
|
|---|
Previous studies from our laboratory have shown that depletion of cellular MsbA or the presence of a conditionally inactivating mutation in MsbA results in the loss of transport of lipid A and glycerophospholipids from the cytoplasmic membrane to the outer membrane (10, 11). These observations suggest that MsbA functions either as a general lipid flippase, catalyzing the transbilayer movement of lipids, or is involved in initiating the transperiplasmic movement of LPS and phospholipids, or both.
Our findings in E. coli support the idea of a more general function for eukaryotic and other MDR-like proteins, to which MsbA is closely related, in the transport of membrane lipids. However, because the three major MDR proteins of animal cells are not essential for cell growth (51) and because mutations do not result in a generalized lipid transport defect, genetic approaches have not been very revealing so far. One important exception is the Mdr2-deficient mouse, which is characterized by a complete absence of phosphatidylcholine in its bile, resulting in liver disease (52), suggesting that MDR2 is a phosphatidylcholine-specific transporter in cells lining the biliary tree. Another relevant example is the selective lipid export function of the ABCA1 protein, which is defective in Tangier disease (45-47). Fibroblasts from patients with Tangier disease appear to have a defect in the export of cellular cholesterol and phospholipids from the plasma membrane to circulating high density lipoproteins (53, 54).
The presence of dozens of additional uncharacterized membrane proteins that are related to the conventional MDRs in animal cells may explain the lack of generalized lipid transport phenotypes seen in the available MDR knockout mice. Some of these additional MDR-like proteins may be able to catalyze lipid transport reactions similar to those catalyzed by the major MDR proteins (55), and they might function singly or in combination.
Several ABC transporters of the MDR family have already been shown to possess intrinsic ATPase activity that is stimulated in the presence of transported substrates. The best example is the mammalian Mdr1 (P-glycoprotein), which possesses an ATPase activity that is stimulated 3-4-fold by various drugs that it is known to transport, including doxorubicin and vinblastine (17, 19). Similarly, the ABCR protein has an ATPase activity that is stimulated 3-4-fold by all-trans-retinal and N-retinylidene-phosphatidylethanolamine (21, 22). ATPase activity has also been reported for the transporter associated with antigen processing (TAP), which is stimulated by peptides (23).
In an effort to study the biochemistry of E. coli MsbA, we have now purified and reconstituted the protein and have characterized its ATPase activity for the first time. The pure protein, when reconstituted with E. coli phospholipids, possesses apparent Km and Vmax values for ATP which are similar to those reported for several other purified ABC transporters (21, 22, 38, 39). Interestingly, micromolar concentrations of hexaacylated lipid A, Kdo2-lipid A, and LPS with an intact core stimulate the basal ATPase activity above the level achieved by glycerophospholipids alone. This stimulation appears to be specific because it is not seen with the same concentrations of lipid X or lipid IVA. The latter are lipid A precursors (Fig. 7) that contain either two or four acyl chains (5, 31, 56, 57), and they are transported to the outer membrane less efficiently than is hexaacylated lipid A (40, 41).
Our prior studies have shown that all phospholipids and lipid A are retained in the inner membrane after the loss of function of MsbA (10, 11). In the present work, detergent-solubilized MsbA exhibited a low basal ATPase activity that was greatly stimulated by the addition of phospholipids (Fig. 3). When MsbA was reconstituted into proteoliposomes of E. coli phospholipids in the absence of lipid A, significant ATPase activity was likewise observed (Fig. 4). However, when lipid A was added to these proteoliposomes, a large increase in ATPase activity was seen (Figs. 5 and 6). These data are consistent with the hypothesis that MsbA is both a phospholipid and a lipid A pump which couples ATP hydrolysis to lipid efflux. MsbA may bind to lipid A more effectively than to glycerophospholipids because of the additional intermolecular contacts that could be achieved with a hexaacylated versus a diacylated lipid. In wild type cells, the entire core domain would be attached to lipid A prior to flip-flop (2, 3), and its presence would have to be accommodated by MsbA.
Recent experiments designed to study phospholipid flip-flop in bacterial membranes and model liposomes have suggested that this process might be energy-independent in bacteria (58, 59). In model membranes, lipid flip-flop occurs at near physiological rates in the absence of ATP or a proton motive force, provided that synthetic membrane-spanning peptides are reconstituted together with the lipids (60). These findings would appear to be at odds with the our results from mutant WD2, in which lipid transport is arrested at the nonpermissive temperature despite the presence of a normal complement of inner membrane proteins (11). One explanation might be that MsbA uses energy from ATP hydrolysis to pump lipids from the outer face of the inner membrane to the outer membrane while facilitating generalized lipid flip-flop in an energy-independent manner (Fig. 1A). Alternatively, extrapolations from studies with isolated or reconstituted membranes may not adequately recapitulate the intracellular environment.
The recent x-ray structure of MsbA (18) demonstrates that the protein forms a homodimer (Fig. 1B). The dimer contains a cleft, facing the cytoplasm in the available structure (18), through which newly synthesized lipids might pass before export (Fig. 1B). A conformational change caused by lipid binding to the membrane-embedded portion of the cleft (Fig. 1B) might be coupled to ATP hydrolysis and transport or vice versa. This model is consistent with our biochemical data (Figs. 3-6) as well as with studies of other MDR proteins. The A270T mutation in WD2 appears to lie near the periplasmic interface of the two monomers (Fig. 1B). One might speculate that MsbA (A270T) cannot form functional dimers at the nonpermissive temperature or that the dimer interface cannot open to expel newly made lipids on the periplasmic surface of the inner membrane.
The availability of purified, catalytically active MsbA lays the groundwork for additional functional studies. If MsbA is indeed a general lipid flippase, as the crystal structure suggests (Fig. 1B) (18), this activity might be detectable in proteoliposomes. LPS or phospholipids could be labeled with fluorescent reporter groups and incorporated into proteoliposomes. MsbA could be then tested for its ability to stimulate the loss of quenchable fluorescence by impermeant reagents (60), indicative of flip-flop. This kind of approach was utilized to demonstrate lipid flippase activity of the ABC transporter LmrA of L. lactis (61). However, LmrA is not required for growth in its native setting (62),2 perhaps because of the presence of additional LmrA-like proteins in Lactococcus (63).
We have been unable to make E. coli cells resistant to several antibiotics, including streptomycin, novobiocin, or erythromycin, following overexpression of MsbA from either low or high copy vectors (data not shown). These observations, coupled with the fact that msbA mutations are not known to be associated with generalized antibiotic resistance phenotypes in E. coli (17), support the notion that E. coli MsbA functions primarily to transport lipid A and glycerophospholipids.
If MsbA is part of a larger molecular machine catalyzing the
transperiplasmic movement of phospholipids and LPS, its transport activity might be detectable only in the presence of acceptor vesicles
and selected outer membrane and periplasmic proteins. A biochemical
assay of this kind might actually lead to the identification and
purification of the relevant additional protein components of the
transport machinery (Fig. 1A). This general strategy has been very successful in the characterization of the LolA-LolE system,
which is responsible for transporting bacterial lipoproteins across the
periplasm of Gram-negative bacteria (64).
| |
ACKNOWLEDGEMENTS |
|---|
We thank Dr. Stephen Trent for preparing lipid IVA and all members of the Raetz laboratory for helpful discussions.
| |
FOOTNOTES |
|---|
* This research was supported in part by National Institutes of Health Grant GM-51310 (to C. R. H. R.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Supported by National Institutes of Health Grant 1 F32
AI-10613-01.
§ To whom correspondence should be addressed: Dept. of Biochemistry, Duke University Medical Center, P. O. Box 3711, Durham, NC 27710. Tel.: 919-684-5326; Fax: 919-684-8885; raetz{at}biochem.duke.edu.
Published, JBC Papers in Press, July 15, 2002, DOI 10.1074/jbc.M205857200
2 W. Konings, personal communication.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: LPS, lipopolysaccharide; ABC, ATP-binding cassette; DDM, dodecyl maltoside; His6, hexahistidine; Kdo, 3-deoxy-D-mannooctulosonic acid; LDAO, N, N-dimethyldodecylamine N-oxide; MDR, multidrug resistance.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Nikaido, H. (1996) in Escherichia coli and Salmonella: Cellular and Molecular Biology (Neidhardt, F. C., ed), 2nd Ed., Vol. 1 , pp. 29-47, American Society for Microbiology, Washington, D. C. |
| 2. | Raetz, C. R. H. (1990) Annu. Rev. Biochem. 59, 129-170[CrossRef][Medline] [Order article via Infotrieve] |
| 3. | Raetz, C. R. H. (1996) in Escherichia coli and Salmonella: Cellular and Molecular Biology (Neidhardt, F. C., ed), 2nd Ed., Vol. 1 , pp. 1035-1063, American Society for Microbiology, Washington, D. C. |
| 4. | Brade, H., Opal, S. M., Vogel, S. N., and Morrison, D. C. (eds) (1999) Endotoxin in Health and Disease , Marcel Dekker, Inc., New York |
| 5. | Raetz, C. R. H., and Whitfield, C. (2002) Annu. Rev. Biochem. 71, 635-700[CrossRef][Medline] [Order article via Infotrieve] |
| 6. |
Galloway, S. M.,
and Raetz, C. R. H.
(1990)
J. Biol. Chem.
265,
6394-6402 |
| 7. |
Onishi, H. R.,
Pelak, B. A.,
Gerckens, L. S.,
Silver, L. L.,
Kahan, F. M.,
Chen, M. H.,
Patchett, A. A.,
Galloway, S. M.,
Hyland, S. A.,
Anderson, M. S.,
and Raetz, C. R. H.
(1996)
Science
274,
980-982 |
| 8. |
Jackman, J. E.,
Fierke, C. A.,
Tumey, L. N.,
Pirrung, M.,
Uchiyama, T.,
Tahir, S. H.,
Hindsgaul, O.,
and Raetz, C. R. H.
(2000)
J. Biol. Chem.
275,
11002-11009 |
| 9. |
Clements, J. M.,
Coignard, F.,
Johnson, I.,
Chandler, S.,
Palan, S.,
Waller, A.,
Wijkmans, J.,
and Hunter, M. G.
(2002)
Antimicrob. Agents Chemother.
46,
1793-1799 |
| 10. |
Zhou, Z.,
White, K. A.,
Polissi, A.,
Georgopoulos, C.,
and Raetz, C. R. H.
(1998)
J. Biol. Chem.
273,
12466-12475 |
| 11. |
Doerrler, W. T.,
Reedy, M. C.,
and Raetz, C. R. H.
(2001)
J. Biol. Chem.
276,
11461-11464 |
| 12. | Karow, M., and Georgopoulos, C. (1993) Mol. Microbiol. 7, 69-79[Medline] [Order article via Infotrieve] |
| 13. | Clementz, T., Bednarski, J., and Raetz, C. R. H. (1995) FASEB J. 9, 1311[Abstract] (abstr.) |
| 14. |
Clementz, T.,
Bednarski, J. J.,
and Raetz, C. R. H.
(1996)
J. Biol. Chem.
271,
12095-12102 |
| 15. | Polissi, A., and Georgopoulos, C. (1996) Mol. Microbiol. 20, 1221-1233[CrossRef][Medline] [Order article via Infotrieve] |
| 16. | van Veen, H. W., Callaghan, R., Soceneantu, L., Sardini, A., Konings, W. N., and Higgins, C. F. (1998) Nature 391, 291-295[CrossRef][Medline] [Order article via Infotrieve] |
| 17. |
Putman, M.,
van Veen, H. W.,
and Konings, W. N.
(2000)
Microbiol. Mol. Biol. Rev.
64,
672-693 |
| 18. |
Chang, G.,
and Roth, C. B.
(2001)
Science
293,
1793-1800 |
| 19. |
Ambudkar, S. V.,
Lelong, I. H.,
Zhang, J.,
Cardarelli, C. O.,
Gottesman, M. M.,
and Pastan, I.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
8472-8476 |
| 20. |
Chang, X. B.,
Hou, Y. X.,
and Riordan, J. R.
(1997)
J. Biol. Chem.
272,
30962-30968 |
| 21. |
Sun, H.,
Molday, R. S.,
and Nathans, J.
(1999)
J. Biol. Chem.
274,
8269-8281 |
| 22. |
Ahn, J.,
Wong, J. T.,
and Molday, R. S.
(2000)
J. Biol. Chem.
275,
20399-20405 |
| 23. |
Gorbulev, S.,
Abele, R.,
and Tampe, R.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
3732-3737 |
| 24. | Miller, J. R. (1972) Experiments in Molecular Genetics , p. 433, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY |
| 25. | Paternostre, M. T., Roux, M., and Rigaud, J. L. (1988) Biochemistry 27, 2668-2677[CrossRef][Medline] [Order article via Infotrieve] |
| 26. | Gonzalez-Romo, P., Sanchez-Nieto, S., and Gavilanes-Ruiz, M. (1992) Anal. Biochem. 200, 235-238[CrossRef][Medline] [Order article via Infotrieve] |
| 27. | Brabetz, W., Muller-Loennies, S., Holst, O., and Brade, H. (1997) Eur. J. Biochem. 247, 716-724[Medline] [Order article via Infotrieve] |
| 28. | Dulbecco, R., and Vogt, M. (1954) J. Exp. Med. 99, 167-182[Abstract] |
| 29. | Bligh, E. G., and Dyer, J. J. (1959) Can. J. Biochem. Physiol. 37, 911-917 |
| 30. |
Raetz, C. R. H.,
and Kennedy, E. P.
(1973)
J. Biol. Chem.
248,
1098-1105 |
| 31. |
Raetz, C. R. H.,
Purcell, S.,
Meyer, M. V.,
Qureshi, N.,
and Takayama, K.
(1985)
J. Biol. Chem.
260,
16080-16088 |
| 32. |
Zhou, Z.,
Lin, S.,
Cotter, R. J.,
and Raetz, C. R. H.
(1999)
J. Biol. Chem.
274,
18503-18514 |
| 33. |
Zhou, Z.,
Ribeiro, A. A.,
Lin, S.,
Cotter, R. J.,
Miller, S. I.,
and Raetz, C. R. H.
(2001)
J. Biol. Chem.
276,
43111-43121 |
| 34. |
Nishijima, M.,
Bulawa, C. E.,
and Raetz, C. R. H.
(1981)
J. Bacteriol.
145,
113-121 |
| 35. |
Radika, K.,
and Raetz, C. R. H.
(1988)
J. Biol. Chem.
263,
14859-14867 |
| 36. |
Garrett, T. A.,
Kadrmas, J. L.,
and Raetz, C. R. H.
(1997)
J. Biol. Chem.
272,
21855-21864 |
| 37. |
Carman, G. M.,
Deems, R. A.,
and Dennis, E. A.
(1995)
J. Biol. Chem.
270,
18711-18714 |
| 38. |
Li, C.,
Ramjeesingh, M.,
Wang, W.,
Garami, E.,
Hewryk, M.,
Lee, D.,
Rommens, J. M.,
Galley, K.,
and Bear, C. E.
(1996)
J. Biol. Chem.
271,
28463-28468 |
| 39. |
Mao, Q.,
Deeley, R. G.,
and Cole, S. P.
(2000)
J. Biol. Chem.
275,
34166-34172 |
| 40. |
Osborn, M. J.,
Rick, P. D.,
and Rasmussen, N. S.
(1980)
J. Biol. Chem.
255,
4246-4251 |
| 41. |
Nishijima, M.,
and Raetz, C. R. H.
(1981)
J. Biol. Chem.
256,
10690-10696 |
| 42. | Lawn, R. M., Wade, D. P., Garvin, M. R., Wang, X., Schwartz, K., Porter, J. G., Seilhamer, J. J., Vaughan, A. M., and Oram, J. F. (1999) J. Clin. Invest. 104, R25-R31 |
| 43. |
Oram, J. F.,
Lawn, R. M.,
Garvin, M. R.,
and Wade, D. P.
(2000)
J. Biol. Chem.
275,
34508-34511 |
| 44. |
Wang, N.,
Silver, D. L.,
Costet, P.,
and Tall, A. R.
(2000)
J. Biol. Chem.
275,
33053-33058 |
| 45. | Bodzioch, M., Orso, E., Klucken, J., Langmann, T., Bottcher, A., Diederich, W., Drobnik, W., Barlage, S., Buchler, C., Porsch-Ozcurumez, M., Kaminski, W. E., Hahmann, H. W., Oette, K., Rothe, G., Aslanidis, C., Lackner, K. J., and Schmitz, G. (1999) Nat. Genet. 22, 347-351[CrossRef][Medline] [Order article via Infotrieve] |
| 46. | Brooks-Wilson, A., Marcil, M., Clee, S. M., Zhang, L. H., Roomp, K., van Dam, M., Yu, L., Brewer, C., Collins, J. A., Molhuizen, H. O., Loubser, O., Ouelette, B. F., Fichter, K., Ashbourne-Excoffon, K. J., Sensen, C. W., Scherer, S., Mott, S., Denis, M., Martindale, D., Frohlich, J., Morgan, K., Koop, B., Pimstone, S., Kastelein, J. J., and Hayden, M. R. (1999) Nat. Genet. 22, 336-345[CrossRef][Medline] [Order article via Infotrieve] |
| 47. | Rust, S., Rosier, M., Funke, H., Real, J., Amoura, Z., Piette, J. C., Deleuze, J. F., Brewer, H. B., Duverger, N., Denefle, P., and Assmann, G. (1999) Nat. Genet. 22, 352-355[CrossRef][Medline] [Order article via Infotrieve] |
| 48. | Ambudkar, S. V., Dey, S., Hrycyna, C. A., Ramachandra, M., Pastan, I., and Gottesman, M. M. (1999) Annu. Rev. Pharmacol. Toxicol. 39, 361-398[CrossRef][Medline] [Order article via Infotrieve] |
| 49. |
Sauna, Z. E.,
Smith, M. M.,
Muller, M.,
and Ambudkar, S. V.
(2001)
J. Biol. Chem.
276,
33301-33304 |
| 50. |
Oliver, D. B.,
Cabelli, R. J.,
Dolan, K. M.,
and Jarosik, G. P.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
8227-8231 |
| 51. | Borst, P., Zelcer, N., and van Helvoort, A. (2000) Biochim. Biophys. Acta 1486, 128-144[Medline] [Order article via Infotrieve] |
| 52. | Smit, J. J. M., Schinkel, A. H., Oude Elferink, R. P. J., Groen, A. K., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., Ottenhoff, R., van der Lugt, N. M. T., van Roon, M. A., van der Valk, M. A., Offerhaus, G. J. A., Berns, A. J. M., and Borst, P. (1993) Cell 75, 451-462[CrossRef][Medline] [Order article via Infotrieve] |
| 53. | Francis, G. A., Knopp, R. H., and Oram, J. F. (1995) J. Clin. Invest. 96, 78-87[Medline] [Order article via Infotrieve] |
| 54. |
Remaley, A. T.,
Schumacher, U. K.,
Stonik, J. A.,
Farsi, B. D.,
Nazih, H.,
and Brewer, H. B., Jr.
(1997)
Arterioscler. Thromb. Vasc. Biol.
17,
1813-1821 |
| 55. | Sprong, H., van der Sluijs, P., and van Meer, G. (2001) Nat. Rev. Mol. Cell. Biol. 2, 504-513[CrossRef][Medline] [Order article via Infotrieve] |
| 56. |
Takayama, K.,
Qureshi, N.,
Mascagni, P.,
Nashed, M. A.,
Anderson, L.,
and Raetz, C. R. H.
(1983)
J. Biol. Chem.
258,
7379-7385 |
| 57. |
Strain, S. M.,
Armitage, I. M.,
Anderson, L.,
Takayama, K.,
Qureshi, N.,
and Raetz, C. R. H.
(1985)
J. Biol. Chem.
260,
16089-16098 |
| 58. |
Huijbregts, R. P.,
de Kroon, A. I.,
and de Kruijff, B.
(1998)
J. Biol. Chem.
273,
18936-18942 |
| 59. |
Hrafnsdottir, S.,
and Menon, A. K.
(2000)
J. Bacteriol.
182,
4198-4206 |
| 60. | Kol, M. A., de Kroon, A. I., Rijkers, D. T., Killian, J. A., and de Kruijff, B. (2001) Biochemistry 40, 10500-10506[CrossRef][Medline] [Order article via Infotrieve] |
| 61. | Margolles, A., Putman, M., van Veen, H. W., and Konings, W. N. (1999) Biochemistry 38, 16298-16306[CrossRef][Medline] [Order article via Infotrieve] |
| 62. |
van Veen, H. W.,
Venema, K.,
Bolhuis, H.,
Oussenko, I.,
Kok, J.,
Poolman, B.,
Driessen, A. J.,
and Konings, W. N.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
10668-10672 |
| 63. |
Bolotin, A.,
Wincker, P.,
Mauger, S.,
Jaillon, O.,
Malarme, K.,
Weissenbach, J.,
Ehrlich, S. D.,
and Sorokin, A.
(2001)
Genome Res.
11,
731-753 |
| 64. | Yakushi, T., Masuda, K., Narita, S., Matsuyama, S., and Tokuda, H. (2000) Nat. Cell Biol. 2, 212-218[CrossRef][Medline] [Order article via Infotrieve] |